Law360, New York (December 12, 2007, 12:00 AM ET) -- A U.S. House of Representatives committee is investigating Merck & Co. Inc. and Schering-Plough Corp. for their delay in releasing the results of a clinical trial for cholesterol drug Vytorin.
Rep. John Dingell (D-Mich.), chairman of the House Committee on Energy and Commerce, and Rep. Bart Stupak (D-Mich.), chairman of the House oversight and investigations subcommittee, told the companies in a letter Tuesday that they are concerned by the delay in releasing the results of the Enhance trial and the “apparent manipulation of trial data.”...
Congress Questions Results Of Cholesterol Study
To view the full article, take a free trial now.
